IMCD NV (IMCD.AS): 2Q’26 first take: Organic GP growth improves to c.7%, EBITA c.6% ahead of cons.; positive

研报英文原文证据摘录

IMCD NV (IMCD.AS): 2Q’26 first take: Organic GP growth improves to c.7%, EBITA c.6% ahead of cons.; positive

ervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the

European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we

consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and

forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as

appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority

of reports are published at irregular intervals as appropriate in the analyst’s judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment

banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co.

LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal

trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and

investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.